he Medicare GLP-1 Bridge: Access, Affordability & the Pharmacist’s Role | TWIRx

TWIRx NEWS 1. Medicare Part D Paid Nearly $588 Million for Ineligible OTC Drugs   A federal audit found that Medicare Part D sponsors made approximately $587.7 million in ineligible payments from 2021 through 2023 for medications that had effectively transitioned from prescription to over-the-counter status.   The HHS Office of Inspector General cited outdated FDA information and the lack of a clear CMS rejection timeline as major contributors.   Why it matters: This exposes a serious coordination problem across FDA data, manufacturers, CMS, health plans and pharmacy claims systems.   Pharmacists may see the rejection or payment issue at the counter, but the failure often begins far upstream.   Read the Fierce Healthcare report Read the HHS-OIG audit 2. FDA Responds to Estradiol Patch Supply Pressure   The FDA is working with six manufacturers to improve access to estradiol transdermal patches amid increased demand.   While FDA has not declared a national shortage, availability varies by product, strength and geographic area. Manufacturers are increasing production through larger batches, added shifts and expanded capacity.   Why it matters: Pharmacists are again serving as the front line of a supply-chain challenge—helping patients locate medication, coordinating with prescribers and identifying alternatives.   Read the Reuters report Read the FDA update 3. New RSV and COVID-19 Guidance Released   The American Academy of Pediatrics and American College of Obstetricians and Gynecologists have issued updated recommendations for RSV and COVID-19 protection during the 2026–2027 respiratory season.   Why it matters: Pharmacists may face conflicting recommendations, patient confusion and questions about eligibility.   Clear counseling and coordination with pediatric and obstetric providers will be critical.   Read the Pharmacy Times report SPECIAL ANNOUNCEMENT FROM OUTCOMES   A special update from Megan Urban and Outcomes.   Outcomes is highlighting new enhancements to its Rx30 pharmacy management platform, including a refreshed user experience, automated data-entry capabilities and support from a dedicated Client Success Team.   The program will explore how these updates can streamline pharmacy workflows, save time and support greater focus on patient care.   Presented by: Dalia Rios and Kaley Lester September 9, 2026 — 1:30 p.m. ET   Register here FEATURED CONVERSATION Building a Bridge to GLP-1 Access   Our featured guest is HaVy Ngo-Hamilton, PharmD, RPh, Senior Pharmacy Director at Buzz Health.   HaVy works at the intersection of pharmacy, healthcare technology, medication affordability and prescription access.   Buzz Health operates platforms including BuzzRx, RxCompare and RxAffect, with a focus on helping connect patients, pharmacies, prescribers and prescription pricing information.   That makes today’s discussion particularly timely. THE MEDICARE GLP-1 BRIDGE   CMS launched the Medicare GLP-1 Bridge on July 1, 2026, to provide eligible Medicare Part D beneficiaries access to selected GLP-1 medications for weight management.   The demonstration runs through December 31, 2027.   Eligible beneficiaries pay $50 for a monthly supply, while the program operates outside the traditional Part D payment flow through centralized prior authorization, claims adjudication and pharmacy payment.   Eligible therapies currently include:   Foundayo® Wegovy® Zepbound®   The bigger issue is not simply GLP-1 coverage.   It is how healthcare connects eligibility, affordability, prior authorization, pharmacy workflow and patient access.   The central question for today’s discussion:   Can we create a medication-access syst